yifutai

益复肽

Report date: 2022/07/15 15:59:00

Base Information

Drug Nameyifutai
Drug Alias NameTAT-N25
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionPI3-kinase class I inhibitors
TargetsPI3-kinase class I
Therapy Area/IndicationsPsoriasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesWuhan Yicheng Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesN/A
Inactive CompaniesWuhan Yicheng Biotechnology Co Ltd
Active IndicationsN/A
Inactive IndicationsPsoriasis

Other Information

ATC CodeN/A
Related LinksN/A